You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: NIA

    PROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosisIPFthe most common of the interstitial lung diseasesoccurs in aboutpeoplewithnew cases diagnosed annually in the USThe typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandaposof the lungs causing an irreversible loss of the tissueandapos s ability to transport oxygenCo morbid pulmonary hypertension is commonly seen in ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GlyTR Therapeutics, Inc.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Discovery of Zika virus therapeutics using a replicon assay

    SBC: MICROBIOTIX, INC.            Topic: R

    ABSTRACT The Zika virusZIKVis the cause of an explosive pandemic of infections across South and Central Americathe Caribbeanand the southeastern region of the United StatesZIKV is a flavivirusa family of small positive strand RNA viruses that includes Dengue virusDENVWest Nile virusWNVYellow fever virusYFVand hepatitis C virusHCVZIKV is transmitted to humans by mosquitoes of the Aedes genusFor the ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Inter-examiner Agreement of a Novel Device for the Measurement of Cervical Dilation in Labor: A Randomized Controlled Trial

    SBC: Elm Tree Medical Inc.            Topic: NICHD

    Measurement of cervical dilation during late pregnancy and labor informs decisions in the management of labor and deliveryPrior published research suggests that practitioners are onlytoaccurate when judging cervical simulatorsWhen measuring laboring womentwo practitionersandaposmeasurements agree onlyof the timeDrEva Martin of Elm Tree Medical Incdeveloped a novel deviceDilaCheckto enable practiti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS

    SBC: ZMK Medical Technologies, Inc.            Topic: 102

    ABSTRACTProstate cancerPCais one of the most commonly occurring forms of canceraccounting forof all cancer in menMulti parametric magnetic resonance imagingmpMRIhas led to improved capabilities for detectinglocalizingand staging PCaCombined with image guided prostate biopsympMRI has helped to improve diagnosis of clinically significant PCawhich helps to reduce mortality as well as unnecessary biop ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100

    SBC: Neonc Technologies, Inc.            Topic: 102

    Project Summary Abstract Many pharmaceutical agents are highly potentbut are unable to exert substantial therapeutic activity against disorders of the brainbecause the blood brain barrierBBBeffectively prevents their access to the site of intracerebral diseaseFor examplethe majority of glioblastoma patientsdespite the best efforts of current medical caredie within two years after diagnosisHencethe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government